Agreement - July 7, 2015
Heptares and AstraZeneca sign agreement
Heptares Therapeutics, a clinical-stage GPCR structure-guided drug discovery and development company and wholly-owned subsidiary of Sosei Group Corporation has entered into a licensing agreement with AstraZeneca under which AstraZeneca will acquire exclusive global rights to develop, manufacture and commercialise the adenosine A2A receptor antagonist, HTL-1071, a small molecule immuno-oncology candidate, and potential additional A2A receptor-blocking […]
Acquisition - April 21, 2015
Novo Nordisk, Janssen Sign Pact
Novo Nordisk A/S and Janssen Biotech, Inc. have signed an agreement that will allow Janssen to acquire an exclusive global license to further develop and commercialize a clinical program focused on therapy within autoimmune diseases. The program targets modulation of certain immune cells via a cell surface receptor (NKG2D receptor), according to Novo Nordisk. The […]
Collaboration - September 19, 2013
Medivir and Ferrer enter agreement
The two companies have entered an agreement for commercializing a new treatment for agitation associated with schizophrenia and bipolar diseases. The license and distribution agreement concerns commercialization of ADASUVE in the Nordic region. In Europe ADASUVE is approved for the treatment of mild to moderate agitation of patients with schizophrenia or bipolar disease. Under the […]
